Trending

Clovis

New price gets Clovis’ PARP inhibitor on the CDF

New price gets Clovis’ PARP inhibitor on the CDF

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to

X

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

ESMO 2019 roundup

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma

X

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

Clovis Oncology has become the latest pharma to invest in radiopharmaceuticals, signing a licensing and collaboration deal with

X

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

https://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

Clovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies

X

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

https://pharmaphorum.com/news/clovis-rubraca/

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving

X

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

https://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/

AZ’s Lynparza becomes first PARP drug approved in breast cancer

AZ’s Lynparza becomes first PARP drug approved in breast cancer

Lynparza first in class approved in breast cancer

X

AZ’s Lynparza becomes first PARP drug approved in breast cancer

https://pharmaphorum.com/news/azs-lynparza-becomes-first-approved-parp-drug-breast-cancer/

Clovis PARP drug gets fast US review in new ovarian cancer use

Clovis PARP drug gets fast US review in new ovarian cancer use

Impressed by survival data, FDA hastens review in expanded patient group

X

Clovis PARP drug gets fast US review in new ovarian cancer use

https://pharmaphorum.com/news/clovis-rubruca-fast-review/

Tesaro’s Zejula primed for EU approval, battle with AZ

Tesaro’s Zejula primed for EU approval, battle with AZ

EU regulators recommend PARP inhibitor Zejula

X

Tesaro’s Zejula primed for EU approval, battle with AZ

https://pharmaphorum.com/news/tesaro/

Rubraca outshines rivals in ovarian cancer maintenance therapy

Rubraca outshines rivals in ovarian cancer maintenance therapy

Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.

X

Rubraca outshines rivals in ovarian cancer maintenance therapy

https://pharmaphorum.com/news/rubraca-outshines-rivals-ovarian-cancer-maintenance/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com